Hypophosphatemia during continuous veno-venous hemofiltration is associated with mortality in critically ill patients with acute kidney injury
Open Access
- 1 January 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Critical Care
- Vol. 17 (5), R205
- https://doi.org/10.1186/cc12900
Abstract
The primary aim of this study was to determine whether hypophosphatemia during continuous veno-venous hemofiltration (CVVH) is associated with the global outcome of critically ill patients with acute kidney injury (AKI). 760 patients diagnosed with AKI and had received CVVH therapy were retrospectively recruited. Death during the 28-day period and survival at 28 days after initiation of CVVH were used as endpoints. Demographic and clinical data including serum phosphorus levels were recorded along with clinical outcome. Hypophosphatemia was defined according to the colorimetric method as serum phosphorus levels < 0.81 mmol/L (2.5 mg/dL), and severe hypophosphatemia was defined as serum phosphorus levels < 0.32 mmol/L (1 mg/dL). The ratio of CVVH therapy days with hypophosphatemia over total CVVH therapy days was calculated to reflect the persistence of hypophosphatemia. The Cox proportional hazard survival model analysis indicated that the incidence of hypophosphatemia or even severe hypophosphatemia was not associated with 28-day mortality independently (p = 0.700). Further analysis with the sub-cohort of patients who had developed hypophosphatemia during the CVVH therapy period indicated that the mean ratio of CVVH therapy days with hypophosphatemia over total CVVH therapy days was 0.58, and the ratio independently associated with the global outcome. Compared with the patients with low ratio (< 0.58), those with high ratio (≥ 0.58) conferred a 1.451-fold increase in 28-day mortality rate (95% CI 1.103–1.910, p = 0.008). Hypophosphatemia during CVVH associated with the global clinical outcome of critically ill patients with AKI. The ratio of CVVH therapy days with hypophosphatemia over total CVVH therapy days was independently associated with the 28-day mortality, and high ratio conferred higher mortality rate.Keywords
This publication has 26 references indexed in Scilit:
- Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapyActa Anaesthesiologica Scandinavica, 2010
- Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapyIntensive Care Medicine, 2004
- Central pontine myelinolysis induced by hypophosphatemia following Wernicke?s encephalopathyNeurological Sciences, 2004
- Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) GroupCritical Care, 2004
- Central pontine myelinolysis temporally related to hypophosphataemiaJournal of Neurology, Neurosurgery & Psychiatry, 2003
- 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions ConferenceIntensive Care Medicine, 2003
- Serum phosphorus levels predict clinical outcome in fulminant hepatic failureLiver Transplantation, 2003
- Severe Hypophosphatemia: Pathophysiologic Implications, Clinical Presentations, and TreatmentMedicine, 2000
- Ventricular Tachycardia in Acute Myocardial InfarctionSouthern Medical Journal, 1994
- Effect of Hypophosphatemia on Diaphragmatic Contractility in Patients with Acute Respiratory FailureThe New England Journal of Medicine, 1985